|No.||Article Type||Article Title||Article Page|
|1||Editorial||In Memoriam: Suk Jung Choo (1964–2023)||371 - 373|
|2||Review||Minimally Invasive Procedure versus Conventional Redo Sternotomy for Mitral Valve Surgery in Patients with Previous Cardiac Surgery: A Systematic Review and Meta-Analysis||374 - 386|
|3||Clinical Research||Clinical Efficacy of a Modified Surgical Procedure in the Treatment of Incompetent Great Saphenous Veins||387 - 393|
|4||Clinical Research||Outcomes after Mechanical Aortic Valve Replacement in Children with Congenital Heart Disease||394 - 402|
|5||Clinical Research||The Prognostic Value of Oligo-Recurrence Following Esophagectomy for Esophageal Cancer||403 - 411|
|6||Commentary||Commentary: The Prognostic Value of Oligo-Recurrence Following Esophagectomy for Esophageal Cancer||412 - 413|
|7||Clinical Research||Bilateral Cardiac Sympathetic Denervation as a Safe Therapeutic Option for Ventricular Arrhythmias||414 - 419|
|8||Clinical Research||A 20-Year Update on the Practice of Thoracic Surgery in Canada: A Survey of the Canadian Association of Thoracic Surgeons||420 - 430|
|9||Clinical Research||Fracture of the Second Rib: An Indirect Sign of Serious Trauma Like Fracture of the First Rib?||431 - 434|
|10||Clinical Research||Comparable Outcomes of Bicuspid Aortic Valves for Rapid-Deployment Aortic Valve Replacement||435 - 444|
|11||Case Report||Valve-Sparing Neo-Aortic Root Replacement for Neo-Aortic Root Dilatation 20 Years after Arterial Switch Operation for Transposition of the Great Arteries: A Case Report||445 - 448|
|12||Case Report||Operative Resection of a Chronic Flail Chest Nonunion Revealing Septic Pseudarthrosis: A Case Report||449 - 451|
|13||Case Report||Enoxaparin as an Anticoagulant in a Multipara with a Mechanical Mitral Valve: A Case Report||452 - 455|
|14||Case Report||A Knife Penetrating the Right Ventricle, Interventricular Septum, and 2 Valves: A Case Report||456 - 459|
Recently revised on 2023, October
The Journal of Chest Surgery (JCS), the official journal of the Korean Society for Thoracic and Cardiovascular Surgery (KTCVS), is a peer-reviewed, open access journal which publishes outstanding articles in thoracic and cardiovascular surgery and related fields. The journal is published bimonthly on the 5th day of January, March, May, July, September, and November. The abbreviated title is J Chest Surg. JCS is committed to providing a place of active communication for all thoracic surgeons, advancing our knowledge on thoracic and cardiovascular surgery including physiology, diagnosis, and treatment, and offering effective treatment and cure to the public ultimately.
Manuscripts submitted to JCS should be prepared according to the following Instructions for Authors. For issues not addressed in these instructions, authors should refer to the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (http://www.icmje.org/recommendations/) from the International Committee of Medical Journal Editors (ICMJE).
JCS is an open access journal that does not charge authors any fees. All costs associated with publishing, including article processing charges, are supported by the publisher.
JCS adheres to the guidelines and best practices published by professional organizations, including ICMJE Recommendations and the Principles of Transparency and Best Practice in Scholarly Publishing (https://doaj.org/bestpractice), and the Good Publication Practice Guideline for Medical Journals (https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=13). Furthermore, all processes of handling research and publication misconduct (or when faced with cases of suspected misconduct) shall follow the applicable COPE flowchart (https://publicationethics.org/resources/flowcharts). Any attempts to duplicate publications or engage in plagiarism will lead to automatic rejection, may prejudice the acceptance of future submissions, and may be highlighted within the pages of the journal.
Clinical research should be conducted in accordance with the World Medical Association’s Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Clinical studies that do not meet the Declaration of Helsinki will not be considered for publication. For human subjects, identifiable information, such as patients’ names, initials, hospital numbers, dates of birth, or other protected healthcare information, should not be disclosed. For animal subjects, research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.
Copies of written informed consents should be kept for studies on human subjects. If the participant is not capable of providing it, a legal guardian, or parent can provide instead. For copies of informed consent, authors can submit the form used in their institutions or use the form provided by JCS. This form is available as a PDF at the JCS website or submission system. Scan the signed and completed form into your computer and then email it to us as an attachment when requested.
All clinical studies involving human participants should include a certificate, agreement, or approval from the Institutional Review Board (IRB). A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. For clinical studies with animal subjects, there should be a certificate, agreement, or approval from the Institutional Animal Care and Use Committee (IACUC). If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB/IACUC approval and study conduct.
All participants in the publication and peer review process—not only authors but also peer reviewers, editors, and Editorial Board members of the journal—must consider their conflicts of interest when fulfilling their roles in the process of article review and publication and must disclose all relationships that could be viewed as potential conflicts of interest. All authors should disclose their conflicts of interest, i.e., (1) financial relationships (such as employment, consultancies, stock ownership, honoraria, and paid expert testimony), (2) personal relationship, (3) academic competition, and (4) intellectual passion.
These conflicts of interest must be included as a footnote on the title page. Authors should certify the disclosure of any conflict of interest with their signatures. Peer reviewers must disclose to editors any conflicts of interest that could bias their opinions of the manuscript, and should recuse themselves from reviewing specific manuscripts if the potential for bias exists. Editors who make final decisions about manuscripts should recuse themselves from editorial decisions if they have conflicts of interest or relationships that pose potential conflicts related to articles under consideration. Other editorial staff members who participate in editorial decisions must provide editors with a current description of their financial interests or other conflicts (as they might relate to editorial judgments) and recuse themselves from any decisions in which a conflict of interest exists. Further guidance is available from COPE (http://www.icmje.org/recommendations/). If undisclosed conflict of interest is suspected in a submitted manuscript or published article, a committee composed of Editorial Board members will be held and discussed, and JCS will follow the process of the applicable COPE flowchart (https://publicationethics.org/resources/flowcharts).
According to the ICMJE recommendation, authorship credit should be based on the following four criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authorsshould meet all four criteria.
Redundant or duplicate publication refers to the publication of a paper that overlaps substantially with one already published. Upon receipt, submitted manuscripts are screened for possible plagiarism or duplicate publication using Crossref Similarity Check. If a paper that might be regarded as duplicate or redundant had already been published in another journal or submitted for publication, the author should notify the fact in advance at the time of submission. Under these conditions, any such work should be referred to and referenced in the new paper. The new manuscript should be submitted together with copies of the duplicate or redundant material to the editorial committee. If redundant or duplicate publication is attempted or occurs without such notification, the submitted manuscript will be rejected immediately. If the editor was not aware of the violations and of the fact that the article had already been published, the editor will announce in the journal that the submitted manuscript had already been published in a duplicate or redundant manner, without seeking the author’s explanation or approval.
Secondary publication of material published in other journals or online may be justifiable and beneficial, especially when intended to disseminate important information to the widest possible audience (e.g., guidelines produced by government agencies and professional organizations in the same or a different language). Secondary publication may also be justifiable in conditions provided by ICMJE Recommendations (https://www.icmje.org/recommendations).
When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, a fraudulent undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, and complaints against editors, the resolution process will follow the flowchart provided by COPE (https://publicationethics.org/guidance/Flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.
The Editorial Board will continuously work to monitor and safeguard publication ethics: provision of guidelines for retracting articles; maintenance of the integrity of the academic record; preclusion of business needs from compromising intellectual and ethical standards; publication of corrections, clarifications, retractions, and apologies when needed; and exclusion of plagiarism and fraudulent data. The editors maintain the following responsibilities: responsibility and authority to reject and accept articles; confirmation of no conflict of interest with respect to articles they reject or accept; promotion of publication of corrections or retractions when errors are found; and preservation of the anonymity of reviewers.
Research Ethics Council is composed of a chairperson of the Publication Committee of the KTCVS and the members of the Committee. The Research Ethics Council is responsible for ensuring that research published in the JCS adheres to ethical standards. They review papers and investigate any issues found, reporting the results to the Board of Directors. The Council members also promote ethical practices by providing education for editors and authors.
Authors must declare that the submitted work is their own and that copyright has not been breached in seeking its publication. Copyright in all published material is owned by the KTCVS. Copyright Release and Author Agreement form must be signed by every author and be submitted with other manuscripts during the first online submission process. The corresponding author is responsible for submitting this form during the submission process. In addition, it is the authors’ responsibility to obtain written permission to reproduce (in all media, including electronic) any material that has appeared previously in another publication. Authors should provide copies of permission letters for any material reproduced from copyrighted publications. Submitted material will not be returned to the author unless specifically requested.
JCS is an open access journal. Articles are distributed under the terms of the Creative Commons License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium if the original work is properly cited. This is in accordance with the Budapest Open Access Initiative definition of open access. For any commercial use of material from the open access version of the journal, permission must be obtained from the KTCVS (Email: email@example.com).
JCS is an open access journal, which means that authors who publish with us are able to freely share their research in various ways, including on preprint servers, social media platforms, at conferences, and in educational materials, in accordance with our open access policy. However, it should be noted that submitting the same manuscript to multiple journals is strictly prohibited.
Any research that deals with a clinical trial should be registered in the primary national clinical trial registry site, such as the Korea Clinical Research Information Service (CRIS; https://cris.nih.go.kr), any other primary national registry site accredited by the World Health Organization (https://www.who.int/clinical-trials-registry-platform), or ClinicalTrials. gov (https://clinicaltrials.gov/), a service of the US National Institutes of Health.
JCS encourages data sharing wherever possible, unless this is prevented by ethical, privacy, or confidentiality matters. Authors wishing to do so may deposit their data in a publicly accessible repository and include a link to the digital object identifier (DOI) within the text of the manuscript. JCS accepts the ICMJE Recommendations for data sharing statement policy (http://www.icmje.org/recommendations/). Authors may refer to the editorial, “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors,” in J Korean Med Sci 2017;32(7): 1051-1053 (https://doi.org/10.3346/jkms.2017.32.7.1051).
JCS ensures the long-term accessibility and preservation of our journal content by archiving it in the National Library of Korea and PubMed Central from the 44th volume, 2011 (https://www.ncbi.nlm.nih.gov/pmc/journals/4000/). This ensures that even if the journal is no longer published, the content will still be available for researchers and scholars.
A preprint can be defined as a version of a scholarly paper that precedes formal peer review and publication in a peer reviewed scholarly journal. JCS allows authors to submit the preprint to the journal. It is not treated as duplicate submission or duplicate publication. JCS recommends authors to disclose it with DOI in the letter to the editor during the submission process. Otherwise, it may be screened from the plagiarism check program—Similarity Check (Crosscheck) or Copy Killer. Submissions of preprints to JCS will undergo the same thorough peer review process as regular submissions. This means that the submissions will be evaluated by experts in the field to ensure the quality and accuracy of the research before they are accepted for publication. If the preprint is accepted for publication, authors are recommended to update the information in the preprint with a link to the published article in JCS, including DOI at JCS. It is strongly recommended that authors cite the article in JCS instead of the preprint in their next submission to journals.
All papers, including those invited by the editor, are subject to a rigorous peer review process. JCS has adopted a double-blind peer review policy, in which the identities of both the authors and reviewers are kept anonymous to each other throughout the review process. However, the editor managing the review process will have visibility of the authors and reviewers’ identities. The Editorial Board selects reviewers based on expertise, publication history, and past reviews. During the peer review process, reviewers can interact directly or exchange information (e.g., via submission systems or email) with only an editor, which is known as “independent review.” An initial decision will normally be made within 4‒6 weeks of receipt of a manuscript. No information about the review process or editorial decision process is published on the article page.
All manuscripts should be submitted online via the journal’s website (https://jchestsurg.org/submission) by the first or corresponding author. Once you have logged into your account, online system will lead you through the submission process in a step-by-step orderly process. Submission instructions are available on the website. In case of any trouble, please contact the editorial office (Email: firstname.lastname@example.org).
All papers, including those invited by the editor, are subject to peer review. JCS only publishes papers that fit its aims and scope, and adhere to the Instructions for Authors. Manuscripts that do not meet these criteria may be returned to the author immediately after submission, without undergoing the review process. Submitted manuscripts are screened for possible plagiarism or duplicate publication by Similarity Check upon arrival. The title page will remain separate from the manuscript throughout the peer review process and will not be sent to the reviewers. It is essential that authors anonymize their manuscripts by removing any identifying information, such as author names or affiliations, before submission to the journal.
After screening, a manuscript is sent to the most two relevant reviewers of the field. In addition, if deemed necessary, a review of statistics may be requested. JCS recommends peer reviewers to follow JCS Review Regulations or the COPE Ethical Guidelines for Peer Reviewers (https://publicationethics.org/resources/guidelines-new/cope-ethical-guidelinespeer-reviewers). The journal uses a double-blind peer review process: the reviewers do not know the identity of the authors, and vice versa. An initial decision will normally be made within 4‒6 weeks of receipt of a manuscript. Revised manuscripts must indicate the alterations that have been made in response to the reviewers’ comments item by item. Failure to resubmit the revised manuscript within 30 days of the editorial decision is regarded as a withdrawal. After the peer review process, the JCS Editorial Board will make the final determination on whether a manuscript is accepted for publication or not. Once a manuscript has been rejected by JCS, it will not be considered for another round of review as a new submission.
Final decisions regarding manuscript publication are made by the editor-in-chief or a designated editor who does not have any relevant conflicts of interest. In the event that an editor has a conflict of interest with a submitted manuscript or with the authors, the manuscript will be handled by one of the other editors who does not have a conflict with the review and who is not at the same institution as the submitting editor. In such circumstances, full masking of the process will be ensured so that the anonymity of the peer reviewers is maintained.
Any appeal against an editorial decision must be made within 2 weeks of the date of the decision letter. Authors who wish to appeal against a decision should contact the editor-in-chief, explaining in detail the reasons for the appeal. All appeals will be discussed with at least one other associate editor. If consensus cannot be reached thereby, an appeal will be discussed at a full editorial meeting. The process of handling complaints and appeals follows the guidelines of COPE available from (https://publicationethics.org/appeals). JCS does not consider second appeals.
The entire manuscript should be written in English. Medical terminology should be written based on the most recent edition of Dorland’s Illustrated Medical Dictionary. The main document with manuscript text and tables should be prepared with an MS-word program.
The cover letter should inform the editor that the submitted material or any portions thereof have not been published previously or are not under consideration for publication elsewhere. It should state any potential conflict of interest that could influence the authors’ interpretation of the data, such as financial support from or connections to pharmaceutical companies, political pressure from interest groups, or academically related issues.
Table 1 shows the recommended maximums of manuscripts according to publication type; however, these requirements are negotiable with the editor.
|Categorya)||Text(word)b)||Abstract(word)||Tables & Figures||References||Keywords|
|Basic/Clinical research||5,000||SA, 250||10||30||5|
|Case report||1,500||UA, 150||3||10||5|
(Letter to the editor)
The title page must include a title, the authors’ names, affiliations, corresponding author’s name and contact information, a running title, and additional information. The corresponding author’s contact information must include the name, address, and email.
A structured abstract is required for original articles and the format should consist of four sections, labeled as “Background,” “Methods,” “Results,” and “Conclusion.” The length should be less than 250 words for original articles and review articles, and less than 150 words for case reports and how-todo-it articles. Up to five keywords should be listed immediately after the abstract to be used as index terms. We strongly recommend the keywords within Medical Subject Heading (MeSH) in Medline (https://meshb.nlm.nih.gov/search).
The main text of the paper may have separate Introduction, Methods, Results, and Discussion sections.
In the text, references should be cited with Arabic numerals in brackets (e.g., , [2,3], [4-6]), numbered in the order cited. In the references section, the references should be numbered and listed in order of appearance in the text. List all authors if there are less than or equal to six authors. List the first three authors followed by “et al.” if there are more than six authors. For every reference, if it has a DOI, the DOI should be included at the end of the reference. References to unpublished material, such as personal communications and unpublished data, should be noted within the text and not cited in the references. Personal communications and unpublished data must include the individual’s name, location, and date of communication. Journal titles should be abbreviated in the style used in Medline. Other types of references not described below should follow Citing Medicine: The NLM Style Guide for Authors, Editors, and Publishers (https://www.ncbi.nlm.nih.gov/books/NBK7256/).
Supplemental material refers to files related to a specific article, which authors supply for publication alongside their article. They should generally be additional pieces to the article that could not be included in the issue or print version, such as appendices, tables, and video material that is impossible to produce within the article. All supplemental materials will be available online, alongside the full-text article. During the submission process, please select “Supplement” for your uploaded file. A listing of supplementary materials must be submitted at the end of the manuscript file and must be cited consecutively in the text of the submitted manuscript.
For specific study designs, such as randomized controlled trials, studies of diagnostic accuracy, meta-analyses, observational studies, and non-randomized studies, we strongly recommend that authors follow and stick to the reporting guidelines relevant to their specific research design. Authors should upload a completed checklist for the appropriate reporting guideline during original submission. Some reliable sources of reporting guidelines are the EQUATOR Network (https://www.equator-network.org/) and NLM (https://www.nlm.nih.gov/services/research_report_guide.html).
After the paper has been accepted for publication, the author(s) should submit the final version of the manuscript. The names and affiliations of the authors should be double-checked, and if the originally submitted image files were of poor resolution, higher resolution image files should be submitted at this time. Symbols (e.g., circles, triangles, squares), letters (e.g., words, abbreviations), and numbers should be large enough to be legible on reduction to the journal’s column widths. All symbols must be defined in the figure caption. If references, tables, or figures are moved, added, or deleted during the revision process, renumber them to reflect such changes so that all tables, references, and figures are cited in numeric order.
Before publication, the manuscript editor will make necessary corrections to ensure that the manuscript adheres to the standard publication format. The corresponding author must respond to the manuscript editor’s revisions within 2 days. If there is a delay in response, the publication of the manuscript may be delayed until the next issue.
The author(s) will receive the final version of the manuscript as a PDF file. Upon receipt, the author(s) must notify the editorial office (or printing office) of any errors found in the file within 2 days. Any errors found after this time are the responsibility of the author(s) and will have to be corrected as an erratum.
To correct errors in published articles, the corresponding author should contact the journal’s editorial office with a detailed description of the proposed correction. Corrections that profoundly affect the interpretation or conclusions of the article will be reviewed by the editors. Corrections will be published as corrigenda (corrections of the author’s errors) or errata (corrections of the publisher’s errors) in a later issue of the journal.
In Seok Jeong , M.D., Woong-Han Kim , M.D., Jong Hyun Baek , M.D., Chang-Hyu Choi , M.D., Chang Woo Choi , M.D., Euy Suk Chung , M.D., Jae Seok Jang , M.D., Woo Sung Jang , M.D., Hanna Jung , M.D., Jae-Seung Jung , M.D., Pil Je Kang , M.D., Dong Jung Kim , M.D., Do Wan Kim , M.D., Hyoung Soo Kim , M.D., Jae Bum Kim , M.D., Woo-Shik Kim , M.D., Young Sam Kim , M.D., Jae Gun Kwak , M.D., Haeyoung Lee , M.D., Seok In Lee , M.D., Jae Woong Lim , M.D., Se Jin Oh , M.D., Tak-Hyuck Oh , M.D., Chun Soo Park , M.D., Kyoung Min Ryu , M.D., Man-Shik Shim , M.D., Joohyung Son , M.D., Kuk Hui Son , M.D., Seunghwan Song , M.D., on behalf of The Korean Society for Thoracic and Cardiovascular Surgery COVID- ECMO Task Force Team
J Chest Surg 2021; 54(1): 2-8
J Chest Surg 2021; 54(3): 165-171
J Chest Surg 2021; 54(5): 333-337
J Chest Surg 2021; 54(6): 454-459
J Chest Surg 2022; 55(1): 61-68
J Chest Surg 2022; 55(2): 151-157